Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment

APMIS

Volumn 118, Issue 9, 2010, Pages 665-673

  YrjÄnÄinen, Heta ^a   HytÖnen, Jukka ^a   Hartiala, Pauliina ^a   Oksi, Jarmo ^a   Viljanen, Matti K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

arthritis; Borrelia burgdorferi; ceftriaxone; Lyme borreliosis; mouse

Indexed keywords

BACTERIAL DNA; CEFTRIAXONE; IMMUNOGLOBULIN G; ROCEPHALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BORRELIA GARINII; BORRELIA INFECTION; CONTROLLED STUDY; FEMALE; FLAB GENE; FOLLOW UP; JOINT; MOUSE; NONHUMAN; OSPA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPIROCHETE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; CEFTRIAXONE; DNA PRIMERS; DNA, BACTERIAL; FLAGELLIN; IMMUNOGLOBULIN G; LYME DISEASE; MICE; POLYMERASE CHAIN REACTION;

EID: 77955953172     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02615.x     Document Type: Article

References (25)

1. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987 107 : 725 31.
2. Weinstein A, Britchkov M. Lyme arthritis and post-Lyme disease syndrome. Curr Opin Rheumatol 2002 14 : 383 7.
3. Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis 1990 162 : 133 8.
4. Yrjänäinen H, Hytönen J, Söderström KO, Oksi J, Hartiala K, Viljanen MK. Persistent joint swelling and Borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment. Microbes Infect 2006 8 : 2044 51.
5. Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol 1993 143 : 959 71.
6. Yrjänäinen H, Hytönen J, Song XY, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3HHe mice. J Infect Dis 2007 195 : 1489 96.
7. Schmidt B, Muellegger RR, Stockenhuber C, Soyer HP, Hoedl S, Luger A, et al. Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. J Clin Microbiol 1996 34 : 1359 63.
8. Ivacic L, Reed KD, Mitchell PD, Ghebranious N. A LightCycler TaqMan assay for detection of Borrelia burgdorferi sensu lato in clinical samples. Diagn Microbiol Infect Dis 2007 57 : 137 43.
9. Viljanen MK, Punnonen J. The effect of storage of antigen-coated polystyrene microwells on the detection of antibodies against Borrelia burgdorferi by enzyme immunoassay (EIA). J Immunol Methods 1989 124 : 137 41.
10. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 2008 52 : 1728 36.
11. Straubinger RK, Summers BA, Chang YF, Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 1997 35 : 111 6.
12. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother 2010 54 : 643 51.
13. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003 301 : 105 7.
14. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 2004 101 : 1333 8.
15. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001 69 : 4572 9.
16. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007 4 : e329.
17. Malawista SE, Barthold SW, Persing DH. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis 1994 170 : 1312 6.
18. Moody KD, Adams RL, Barthold SW. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother 1994 38 : 1567 72.
19. Pavia C, Inchiosa MA, Jr., Wormser GP. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob Agents Chemother 2002 46 : 132 4.
20. Liang FT, Brown EL, Wang T, Iozzo RV, Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol 2004 165 : 977 85.
21. Cabello FC, Godfrey HP, Newman SA. Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol 2007 15 : 350 4.
22. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 2008 5 : 40.
23. Brorson O, Brorson SH. Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection 1997 25 : 240 6.
24. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 2008 52 : 1728 36.
25. Eisendle K, Grabner T, Zelger B. Focus floating microscopy: "gold standard" for cutaneous borreliosis? Am J Clin Pathol 2007 127 : 213 22.